Acquired resistance to first-line therapies remains one of the most stubborn barriers in advanced liver cancer treatment. Understanding exactly how tumor cells rewire their metabolism to evade targeted drugs could open entirely new combination strategies — and this research identifies a surprisingly specific molecular culprit linking fat metabolism to therapeutic escape.
Using transcriptomic and metabolomic profiling of lenvatinib-resistant hepatocellular carcinoma (HCC) cells, investigators pinpointed ACSS2 — an enzyme that converts acetate into acetyl-CoA — as the strongest molecular correlate of resistance. The mechanism is mechanistically precise: ACSS2 upregulation drives elevated palmitate biosynthesis, and the resulting palmitate molecules are used to chemically modify the EGFR receptor through a process called palmitoylation. This lipid modification physically shields EGFR from ubiquitin-tagged degradation, artificially extending the receptor's lifespan and sustaining the oncogenic signaling cascade that promotes tumor survival. Critically, ACSS2 knockdown restored lenvatinib sensitivity in resistant cell lines, while its overexpression was sufficient to confer resistance in previously sensitive cells. Pharmacological ACSS2 inhibition synergized with lenvatinib in two distinct mouse HCC models.
This finding is notable because it bridges metabolic reprogramming and post-translational receptor regulation in a single, druggable axis — a connection that has been underexplored in HCC specifically. ACSS2 has attracted growing interest in oncology for its role in histone acetylation and lipid metabolism, but its function as a palmitoylation enabler protecting receptor tyrosine kinases represents a less-characterized dimension. The broader research landscape suggests palmitoylation is increasingly recognized as a cancer resistance mechanism, yet targeted interventions remain early-stage. Key limitations include the reliance on subcutaneous and hydrodynamic mouse models rather than orthotopic or patient-derived xenografts, and the absence of human clinical validation. This is incremental-to-notable preclinical work with genuine translational potential, though considerable development lies ahead before clinical application.